CONSORT

CONSORT is an evidence-based, minimum set of recommendations for reporting randomized controlled trials to improve transparency, reproducibility, and critical appraisal. It provides a structured checklist and flow diagram intended for authors, editors, peer reviewers, funders, and readers to assess trial design, conduct, analysis, and interpretation. Widely endorsed by journals, publishers, and regulatory bodies, the guideline interacts with related initiatives in clinical research, publishing standards, and health policy.

Background

The initiative emerged from methodological discussions at meetings involving groups from institutions such as the National Institutes of Health, Medical Research Council (United Kingdom), World Health Organization, Cochrane Collaboration, and the European Medicines Agency about poor reporting in randomized trials. Influential epidemiologists and statisticians from organizations including Harvard University, Johns Hopkins University, University of Oxford, University of Cambridge, McMaster University, Stanford University, and University of Toronto contributed to early development. Early deliberations referenced landmark works and figures associated with evidence synthesis like Archie Cochrane, Iain Chalmers, David Sackett, and committees linked to CONSORT-adjacent endeavors such as the International Committee of Medical Journal Editors and the Equator Network. Major medical journals including The Lancet, The New England Journal of Medicine, BMJ, JAMA, and Annals of Internal Medicine played key roles in dissemination. The guideline’s origins relate to concerns raised by systematic reviewers and trialists following high-profile trials and regulatory cases involving institutions like the Food and Drug Administration and the European Commission.

CONSORT Statement and Checklist

The core product is a statement accompanied by a 25-item checklist and a flow diagram that map to trial elements such as enrolment, allocation, follow-up, and analysis. Items were developed and refined by consensus panels comprising researchers affiliated with University College London, Karolinska Institutet, Yale University, Columbia University, Duke University, University of California, San Francisco, and Imperial College London. The checklist addresses trial features often referenced in guidance from bodies like International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and reporting expectations of publishers such as Elsevier, Springer Nature, and Wiley-Blackwell. The flow diagram echoes participant flow depictions used in major trials led by groups at Mayo Clinic, Cleveland Clinic, Vanderbilt University Medical Center, and Massachusetts General Hospital. CONSORT-related items intersect with statistical standards promoted by societies including the American Statistical Association and the Royal Statistical Society.

Extensions and Adaptations

To accommodate diverse trials, the guideline spawned extensions for specific designs, interventions, and data types. Examples include extensions for cluster trials, non-inferiority and equivalence trials, pragmatic trials, pilot and feasibility trials, and adaptive designs. Contributors to extensions have included researchers at Oxford Vaccine Group, Imperial College Business School, Scripps Research, Karolinska University Hospital, University of Melbourne, Monash University, University of Sydney, University of Edinburgh, and Trinity College Dublin. Other extensions cover reporting of harms, harms-related analyses, and abstracts, linking to standards used by organizations such as the European Society of Cardiology, American Heart Association, World Psychiatric Association, and disease-specific networks like the Global Alliance for Vaccines and Immunization. Adaptations have informed trial registries run by ClinicalTrials.gov, EU Clinical Trials Register, and national regulators.

Implementation and Impact

Implementation has involved journal endorsement, editorial policies, author checklists, and training in methodology at institutions like Harvard T.H. Chan School of Public Health, Johns Hopkins Bloomberg School of Public Health, London School of Hygiene & Tropical Medicine, and Yale School of Public Health. Empirical evaluations by researchers at McMaster University, University of Bristol, University of Glasgow, and Università di Milano assessed reporting quality before and after endorsement by periodicals including PLOS Medicine, BMJ Open, The BMJ, and specialty journals in cardiology, oncology, and psychiatry. Funders such as the Wellcome Trust, Bill & Melinda Gates Foundation, National Institute for Health Research, and Canadian Institutes of Health Research have recommended compliance with reporting standards. Systematic review groups at Cochrane and guideline developers at National Institute for Health and Care Excellence have used CONSORT-compliant reports for evidence synthesis and guideline development. Meta-research by teams at Stanford Medicine and University of Pennsylvania examined CONSORT’s influence on reproducibility crises highlighted by commentators from Nature, Science, and The New York Times.

Criticisms and Limitations

Critiques address incomplete uptake, inconsistent adherence, and variable enforcement by journals such as those in specialty fields represented by organizations like the American College of Physicians and the European Respiratory Society. Methodologists from University of Bern, University of Zurich, ETH Zurich, and Leiden University Medical Center have noted persistent reporting gaps in allocation concealment, blinding, and harms reporting. Critics point to challenges in applying the checklist to complex interventions in settings overseen by institutions like Doctors Without Borders, International Committee of the Red Cross, and global health consortia. Debates involving ethicists and regulators from Hastings Center, Nuffield Council on Bioethics, and national health services raise issues about transparency versus participant confidentiality and commercial confidentiality advocated by pharmaceutical companies such as Pfizer, Novartis, Roche, and Johnson & Johnson. Ongoing methodological work at universities including Brown University and University of Chicago aims to refine guidance and integration with reporting platforms and registries.

Category:Research reporting guidelines